1
|
Weisert M, Su JA, Menteer J, Shaddy RE, Kantor PF. Drug Treatment of Heart Failure in Children: Gaps and Opportunities. Paediatr Drugs 2022; 24:121-136. [PMID: 35084696 DOI: 10.1007/s40272-021-00485-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/08/2021] [Indexed: 12/11/2022]
Abstract
Medical therapy for pediatric heart failure is based on a detailed mechanistic understanding of the underlying causes, which are diverse and unlike those encountered in most adult patients. Diuresis and improved perfusion are the immediate goals of care in the child with acute decompensated heart failure. Conversion to maintenance oral therapy for heart failure is based on the results of landmark studies in adults, as well as recent pediatric clinical trials and heart failure guidelines. There will continue to be an important role for newer drugs, some of which are in active trials in adults, and some of which are already approved for use in children. The need to plan for clinical trials in children during drug development for heart failure is emphasized.
Collapse
Affiliation(s)
- Molly Weisert
- Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- Division of Cardiology, Heart Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA
| | - Jennifer A Su
- Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- Division of Cardiology, Heart Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA
| | - Jondavid Menteer
- Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- Division of Cardiology, Heart Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA
| | - Robert E Shaddy
- Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- Division of Cardiology, Heart Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA
| | - Paul F Kantor
- Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
- Division of Cardiology, Heart Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
| |
Collapse
|
2
|
Sobeih AA, El-Saiedi SA, Abdel Khalek NS, Attia SA, Hanna BM. Parameters affecting outcome of paediatric cardiomyopathies in the intensive care unit: experience of an Egyptian tertiary centre over 7 years. Libyan J Med 2021; 15:1822073. [PMID: 33048664 PMCID: PMC7594879 DOI: 10.1080/19932820.2020.1822073] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Introduction: Paediatric cardiomyopathies are rare but serious and often life-threatening conditions. In the absence of cardiac transplant and ventricular assist device as treatment options in our region, it is very important to identify patients at higher risk. The aim of this study was to determine the outcome of patients diagnosed with cardiomyopathies and their prognostic indicators. Patients and methods: This study included 92 cases representing all patients diagnosed with cardiomyopathy who were admitted into the pediatric cardiac intensive care unit during the period from January 2012 to September 2018. The patients were classified into two groups according to the outcome: the first group comprised 69 patients who survived, and the second group comprised 23 patients who died. All medical records were reviewed, and data were recorded and analysed. Results: Patients with cardiomyopathies represented 8.6% (92/1071) of all patients with cardiac diseases who were admitted in the study period and in the target age group (0.5-12 years). Dilated cardiomyopathy (DCM) was the most frequent type of cardiomyopathy among the admitted patients (80 patients), while 6 patients were diagnosed with hypertrophic cardiomyopathy (HCM), 4 were diagnosed with restrictive cardiomyopathy (RCM), and only 2 were diagnosed with mixed DCM-RCM. Seventy patients required inotropic support (76.1%). Assisted mechanical ventilation was used on 15 patients (16.3%). Twenty-three patients (25.0%) died during the 7-year study period. Conclusions Conclusions The occurrence of hypotension, abnormally high liver enzymes, the need for mechanical ventilation and the need for multiple inotropic drugs were found to be statistically significant predictors of mortality, while age, sex, fractional shortening, ejection fraction, presence of mitral regurgitation, mural thrombus, electrolyte disturbance and arrhythmias did not predict or affect patients' outcomes.
Collapse
Affiliation(s)
- Alaa A Sobeih
- Pediatric Cardiology Division, Department of Paediatrics, Faculty of Medicine, Cairo University , Giza, Egypt
| | - Sonia A El-Saiedi
- Pediatric Cardiology Division, Department of Paediatrics, Faculty of Medicine, Cairo University , Giza, Egypt
| | - Noha S Abdel Khalek
- Department of Pediatrics, Faculty of Medicine, Cairo University , Giza, Egypt
| | - Shereen A Attia
- Neonatal Intensive Care Unit, Om El-Atebaa Hospital , Cairo, Egypt
| | - Baher M Hanna
- Pediatric Cardiology Division, Department of Paediatrics, Faculty of Medicine, Cairo University , Giza, Egypt
| |
Collapse
|
3
|
Longitudinal Prediction of Transplant-Free Survival by Echocardiography in Pediatric Dilated Cardiomyopathy. Can J Cardiol 2020; 37:867-876. [PMID: 33347978 DOI: 10.1016/j.cjca.2020.12.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 12/09/2020] [Accepted: 12/10/2020] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND The prognostic significance of serial echocardiography and its rate of change in children with dilated cardiomyopathy (DCM) is incompletely defined. METHODS We retrospectively analysed up to 4 serial echocardiograms. Associations between mortality/transplant and echocardiographic parameters over time and between outcomes and the rate of change of echocardiographic parameters were analysed. Estimation of patient-specific intercepts and slopes was done using linear regression models. RESULTS Fifty-seven DCM children were studied (50% male; median age, 0.6 year; average follow-up, 2.1 ± 2.4 years). The median time to transplant or death was 2.0 years. Increased left ventricular (LV) diastolic (LVEDD) and systolic (LVESD) dimensions and myocardial performance index (MPI) were associated with increased mortality and transplant risk. Increased LV ejection fraction, mitral E-deceleration time, right ventricular (RV) fractional area change, and tricuspid annular plane systolic excursion were associated with reduced mortality and transplant risk. Transplant/mortality likelihood increased by 41.6% and 19.8% for each unit increase in LVEDD and LVESD z scores, respectively (LVEDD: hazard ratio [HR], 1.416; 95% confidence interval [CI], 1.285-1.560; P < 0.001; LVESD: HR, 1.198; 95% CI, 1.147-1.251; P < 0.001). A higher monthly change in LVESD z score increased transplant/mortality likelihood by 85.6% (HR, 1.856; 95% CI, 1.572-2.191; P = 0.015). Greater changes in mitral E/e' (HR, 0.707; 95% CI, 0.636-0.786; P < 0.001) and RV MPI (HR, 0.412; 95% CI, 0.277-0.613; P < 0.001) were associated with reduced mortality and transplant risk. CONCLUSIONS LV and RV systolic and diastolic dimensions and function over time and their rate of change are associated with risk for transplant and mortality in childhood DCM. Serial changes in these parameters may be useful to predict clinical outcomes.
Collapse
|
4
|
Price JF, Jeewa A, Denfield SW. Clinical Characteristics and Treatment of Cardiomyopathies in Children. Curr Cardiol Rev 2016; 12:85-98. [PMID: 26926296 PMCID: PMC4861947 DOI: 10.2174/1573403x12666160301115543] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2015] [Revised: 11/05/2015] [Accepted: 02/29/2016] [Indexed: 01/10/2023] Open
Abstract
Cardiomyopathies are diseases of the heart muscle, a term introduced in 1957 to identify a group of myocardial diseases not attributable to coronary artery disease. The definition has since been modified to refer to structural and or functional abnormalities of the myocardium where other known causes of myocardial dysfunction, such as systemic hypertension, valvular disease and ischemic heart disease, have been excluded. In this review, we discuss the pathophysiology, clinical assessment and therapeutic strategies for hypertrophic, dilated and hypertrophic cardiomyopathies, with a particular focus on aspects unique to children.
Collapse
Affiliation(s)
- Jack F Price
- Lillie Frank Abercrombie Section of Pediatric Cardiology, Section of Critical Care Medicine, Baylor College of Medicine, Texas Children's Hospital, 6621 Fannin MC19345C, Houston.
| | | | | |
Collapse
|
5
|
Miyamoto SD, Karimpour-Fard A, Peterson V, Auerbach SR, Stenmark KR, Stauffer BL, Sucharov CC. Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy. J Heart Lung Transplant 2015; 34:724-33. [PMID: 25840506 DOI: 10.1016/j.healun.2015.01.979] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Revised: 12/05/2014] [Accepted: 01/24/2015] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND MicroRNAs (miRNAs) are short regulatory RNAs that control gene expression through interacting with the 3'UTR of target messenger RNAs. The purpose of this study was to determine if circulating miRNAs are useful biomarkers of outcome in children with dilated cardiomyopathy (DCM). METHODS An array for 754 miRNAs and real time polymerase chain reaction confirmation of select miRNAs were performed. Serum from 55 children <18 years old with DCM was analyzed. Samples were drawn from all patients with DCM when undergoing heart transplant evaluation and/or at the time of transplantation. Patients with DCM were categorized based on when their blood was drawn (Pre-Transplant or Transplant) and outcome (Transplant/died or Recovered). RESULTS Two miRNAs were significantly up-regulated (hsa-miR-155 and hsa-miR-636) and 2 miRNAs were down-regulated (hsa-miR-646 and hsa-miR-639) in patients with DCM who were transplanted or died compared with patients with DCM who recovered their ventricular function. Receiver operator curves, performed for differences in any 1 of these 4 differentially regulated miRNAs in patients who were transplanted or died compared with patients who recovered, resulted in an area under the receiver operating characteristic curve of 0.875 for the Pre-Transplant blood draw time point and an area under the receiver operating characteristic curve of 0.93 for the day of Transplant time point. CONCLUSIONS We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population.
Collapse
Affiliation(s)
- Shelley D Miyamoto
- Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado.
| | | | | | - Scott R Auerbach
- Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado
| | - Kurt R Stenmark
- Cardiovascular Pulmonary Research Laboratory, University of Colorado, Denver, Colorado
| | - Brian L Stauffer
- Division of Cardiology; Division of Cardiology, Denver Health and Hospital Authority, Denver, Colorado
| | | |
Collapse
|
6
|
Dubin AM, Berul CI. Electrophysiological interventions for treatment of congestive heart failure in pediatrics and congenital heart disease. Expert Rev Cardiovasc Ther 2014; 5:111-8. [PMID: 17187462 DOI: 10.1586/14779072.5.1.111] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Heart failure therapy, while well tested in the adult population, therapeutic interventions are less well defined in the pediatric population. Several treatment strategies are available for the adult patient with heart failure, thought few of these therapies have been proven in children. Morbidity and mortality in the pediatric population with a failing heart is significant, and rhythm management as well as strategies to improve hemodynamics are important in the care of these children. This review will address issues of rhythm management and resynchronization therapy in pediatric and congenital heart disease patients with heart failure.
Collapse
Affiliation(s)
- Anne M Dubin
- Stanford University, 750 Welch Rd., Suite 305, Palo Alto, CA 94304, USA.
| | | |
Collapse
|
7
|
Alexander PM, Daubeney PE, Nugent AW, Lee KJ, Turner C, Colan SD, Robertson T, Davis AM, Ramsay J, Justo R, Sholler GF, King I, Weintraub RG. Long-Term Outcomes of Dilated Cardiomyopathy Diagnosed During Childhood. Circulation 2013; 128:2039-46. [DOI: 10.1161/circulationaha.113.002767] [Citation(s) in RCA: 107] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Existing studies of childhood dilated cardiomyopathy deal mainly with early survival. This population-based study examines long-term outcomes for children with dilated cardiomyopathy.
Methods and Results—
The diagnosis of dilated cardiomyopathy was based on clinical, echocardiographic, and pathological findings. The primary study end point included time to the combined outcome of death or cardiac transplantation. There were 175 patients 0 to <10 years of age at the time of diagnosis. Survival free from death or transplantation was 74% (95% confidence interval, 67–80) 1 year after diagnosis, 62% (95% confidence interval, 55–69) at 10 years, and 56% (95% confidence interval, 46–65) at 20 years. In multivariable analysis, age at diagnosis <4 weeks or >5 years, familial cardiomyopathy, and lower baseline left ventricular fractional shortening
Z
score were associated with increased risk of death or transplantation, as was lower left ventricular fractional shortening
Z
score during follow-up. At 15 years after diagnosis, echocardiographic normalization had occurred in 69% of surviving study subjects. Normalization was related to higher baseline left ventricular fractional shortening
Z
score, higher left ventricular fractional shortening
Z
score during follow-up, and greater improvement in left ventricular fractional shortening
Z
score. Children with lymphocytic myocarditis had better survival and a higher rate of echocardiographic normalization. At the latest follow-up, 100 of 104 of survivors (96%) were free of cardiac symptoms, and 83 (80%) were no longer receiving pharmacotherapy.
Conclusions—
Death or transplantation occurred in 26% of patients with childhood dilated cardiomyopathy within 1 year of diagnosis and ~1% per year thereafter. Risk factors for death or transplantation include age at diagnosis, familial cardiomyopathy, and severity of left ventricular dysfunction. The majority of surviving subjects are well and free of cardiac medication.
Collapse
Affiliation(s)
- Peta M.A. Alexander
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Piers E.F. Daubeney
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Alan W. Nugent
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Katherine J. Lee
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Christian Turner
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Steven D. Colan
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Terry Robertson
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Andrew M. Davis
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - James Ramsay
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Robert Justo
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Gary F. Sholler
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Ingrid King
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Robert G. Weintraub
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| |
Collapse
|
8
|
Molina KM, Shrader P, Colan SD, Mital S, Margossian R, Sleeper LA, Shirali G, Barker P, Canter CE, Altmann K, Radojewski E, Tierney ESS, Rychik J, Tani LY. Predictors of disease progression in pediatric dilated cardiomyopathy. Circ Heart Fail 2013; 6:1214-22. [PMID: 24132734 DOI: 10.1161/circheartfailure.113.000125] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Despite medical advances, children with dilated cardiomyopathy (DCM) remain at high risk of death or need for cardiac transplantation. We sought to identify predictors of disease progression in pediatric DCM. METHODS AND RESULTS The Pediatric Heart Network evaluated chronic DCM patients with prospective echocardiographic and clinical data collection during an 18-month follow-up. Inclusion criteria were age <22 years and DCM disease duration >2 months. Patients requiring intravenous inotropic/mechanical support or listed status 1A/1B for transplant were excluded. Disease progression was defined as an increase in transplant listing status, hospitalization for heart failure, intravenous inotropes, mechanical support, or death. Predictors of disease progression were identified using Cox proportional hazards modeling and classification and regression tree analysis. Of the 127 patients, 28 (22%) had disease progression during the 18-month follow-up. Multivariable analysis identified older age at diagnosis (hazard ratio=1.14 per year; P<0.001), larger left ventricular (LV) end-diastolic M-mode dimension z-score (hazard ratio=1.49; P<0.001), and lower septal peak systolic tissue Doppler velocity z-score (hazard ratio=0.81; P=0.01) as independent predictors of disease progression. Classification and regression tree analysis stratified patients at risk of disease progression with 89% sensitivity and 94% specificity based on LV end-diastolic M-mode dimension z-score ≥7.7, LV ejection fraction <39%, LV inflow propagation velocity (color M-mode) z-score <-0.28, and age at diagnosis ≥8.5 months. CONCLUSIONS In children with chronic stable DCM, a combination of diagnosis after late infancy and echocardiographic parameters of larger LV size and systolic and diastolic function predicted disease progression. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00123071.
Collapse
|
9
|
Lee GH, Kim YH. Cerebral Ischemic Stroke in an Infant with Acute Myocarditis - A Case Report -. Korean J Crit Care Med 2013. [DOI: 10.4266/kjccm.2013.28.2.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- Ga Hyun Lee
- Department of Pediatrics, Keimyung University School of Medicine, Daegu, Korea
| | - Yeo Hyang Kim
- Department of Pediatrics, Keimyung University School of Medicine, Daegu, Korea
| |
Collapse
|
10
|
|
11
|
Hill KD, Atkinson JB, Doyle TP, Dodd D. Routine performance of endomyocardial biopsy decreases the incidence of orthotopic heart transplant for myocarditis. J Heart Lung Transplant 2009; 28:1261-6. [PMID: 19782583 DOI: 10.1016/j.healun.2009.06.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2008] [Revised: 06/16/2009] [Accepted: 06/26/2009] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND In critically ill children presenting with dilated cardiomyopathy (DCM), the presence of myocarditis predicts an improved chance of myocardial recovery. Noninvasive differentiation of myocarditis from other causes of DCM is difficult. However, sensitivity of endomyocardial biopsy has been questioned. METHODS We reviewed clinical, echocardiographic, catheterization, and pathology data from all children admitted to the intensive care unit with DCM undergoing orthotopic heart transplantation since the inception of our transplant program in 1987 and all patients with definitively diagnosed myocarditis presenting since 1996. RESULTS Thirty-six patients with DCM underwent orthotopic heart transplantation. Cellular infiltrate was present in 3 of 36 (8.3%) explanted specimens. Pre-transplant biopsy was performed in 81%. No explanted heart demonstrated infiltrates after a negative biopsy. One biopsy was positive with negative explant histology after transplant 6 months later. No patient with biopsy-proven myocarditis died while listed for transplantation. Eleven additional patients with myocarditis did not undergo transplant. Ten have survived and experienced complete (n = 9) or near complete (n = 1) recovery of myocardial function. One patient died shortly after presentation from fulminant myocarditis. The 10 transplant-free survivors could not be easily distinguished from our transplant cohort by clinical features at presentation. CONCLUSION The incidence of cellular infiltrate in explanted hearts was significantly lower than that previously reported. Potentially, our aggressive myocarditis diagnostic protocol was useful in therapeutic stratification as a cohort of myocarditis patients avoided transplant and experienced complete recovery of myocardial function despite being difficult to distinguish clinically from our DCM transplant cohort at presentation.
Collapse
Affiliation(s)
- Kevin D Hill
- Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee 37232, USA.
| | | | | | | |
Collapse
|
12
|
Defects in long chain fatty acid oxidation presenting as severe cardiomyopathy and cardiogenic shock in infancy. Cardiol Young 2009; 19:540-2. [PMID: 19691901 DOI: 10.1017/s104795110999134x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Inborn errors of fatty acid metabolism are important causes of reversible cardiomyopathy in infancy. Disorders in long chain fatty acid oxidation can lead to cardiomyopathy, as fatty acid beta oxidation is the major source of myocardial energy after birth. We present 2 cases of such disorders with cardiac manifestations during infancy, which responded well to a diet low in long chain fatty acids.
Collapse
|
13
|
Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am J Cardiol 2009; 104:281-6. [PMID: 19576361 DOI: 10.1016/j.amjcard.2009.03.033] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2008] [Revised: 03/12/2009] [Accepted: 03/12/2009] [Indexed: 11/23/2022]
Abstract
In 40% of children with symptomatic idiopathic dilated cardiomyopathy (IDC), medical therapy fails within 2 years of diagnosis. Strong evidence-based therapies are not available for these children, and how evidence-based therapies for adults with IDC should be applied to children is unclear. Using data from the National Heart, Lung, and Blood Institute's Pediatric Cardiomyopathy Registry, we compared practice patterns of initial therapies for children with IDC diagnosed from 1990 to 1995 (n = 350) and from 2000 to 2006 (n = 219). At diagnosis, 73% had symptomatic heart failure (HF), and 7% had > or =1 family member with IDC. Anti-HF medications were most commonly prescribed initially. Anti-HF medication use was similar across the 2 periods (84% and 87%, respectively), as was angiotensin-converting enzyme inhibitor use (66% and 70%, respectively). These medications were used more commonly in children with greater left ventricular dilation and poorer left ventricular fractional shortening and functional class (p <0.001). Beta-blocker use was 4% to 18% over the 2 periods. Treatments for pediatric IDC have changed little over the previous 25 years. Anti-HF medications remain the most common treatment, and they are often given to children with asymptomatic left ventricular dysfunction. Children with asymptomatic left ventricular dysfunction are often not offered angiotensin-converting enzyme inhibitors without echocardiographic evidence of advanced disease. In conclusion, therapeutic clinical trials are strongly indicated because practice variation is substantial and medical outcomes in these children have not improved in the previous several decades.
Collapse
|
14
|
HAMILTON ROBERTM, AZEVEDO EDUARDOR. Sudden Cardiac Death in Dilated Cardiomyopathies. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2009; 32 Suppl 2:S32-40. [DOI: 10.1111/j.1540-8159.2009.02382.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Clinical profiles and outcomes for Omani children with dilated cardiomyopathy seen in a regional referral hospital. Cardiol Young 2009; 19:145-51. [PMID: 19224668 DOI: 10.1017/s1047951109003497] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To provide an account of paediatric dilated cardiomyopathy as seen in a region of Oman, analysing the data from 32 consecutive children who received care in our unit between January, 1999, and August, 2007. RESULTS The patients, of whom 17 were male, were aged between 5 weeks and 8 years at presentation, with a median of 7 months. The disease was deemed to be myocarditis-induced in one-third, and idiopathic in half. Cardiac failure, seen in almost four-fifths, was the most frequent presenting feature. Correspondingly, the cardiothoracic ratios were increased, to a mean of 68% in 20 infants, and to 65% in 8 older children, and the left ventricular ejection fraction depressed, to a mean of 41%, in the 23 patients in whom it could be evaluated. Patients in cardiac failure received various combinations of diuretics, inotropes, and captopril. In addition, 6 received carvedilol, and 3 intravenous immunoglobulin. Death occurred in 2 patients shortly after admission, one left the hospital against medical advice, and the remaining 29 were followed-up for a mean of 37 months, with a range from 2 to 102 months. Recovery was noted in one-third of the patients, with one-quarter showing improvement but still requiring anti-failure medications. Slightly over two-fifths died. Of those with the idiopathic form, 40% died, with death occurring in 46% of those deemed to have myocarditis-induced disease, in half of those presenting in infancy, and in 57% of those who presented in cardiac failure. CONCLUSION Dilated cardiomyopathy was often severe in our patients, albeit that the cause was frequently uncertain, and the response to standard anti-failure treatment unsatisfactory. Efforts should be intensified for unravelling its aetiology and improving medical treatment.
Collapse
|
16
|
Abstract
There are several options now available for the management of arrhythmias and ventricular dysfunction in pediatric patients with heart failure. A hybrid approach that combines the expertise of heart failure and electrophysiology specialists may be well suited for the optimal management of these complex patients. Medical and device therapies may be synergistic in decreasing the morbidity and mortality in pediatric heart failure. Pediatric electrophysiology can now potentially offer therapies that can help prevent both arrhythmic and pump failure deaths, as well as improve functional capacity and quality of life. These therapies and the available supporting data relevant to pediatrics will be the focus of this review.
Collapse
|
17
|
Andrews RE, Fenton MJ, Ridout DA, Burch M. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United kingdom and Ireland. Circulation 2007; 117:79-84. [PMID: 18086928 DOI: 10.1161/circulationaha.106.671735] [Citation(s) in RCA: 160] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND We undertook the first prospective, national, multicenter study to describe the incidence and outcome of heart muscle disease-induced heart failure in children. METHODS AND RESULTS Data were collected on patients admitted to a hospital through 2003 with a first episode of heart failure in the absence of congenital heart disease. All 17 pediatric cardiac centers in the United Kingdom and Ireland participated. Follow-up data were obtained to a minimum of 1 year. The incidence was 0.87/100,000 population <16 years (n=104; 53 girls; 95% confidence interval 0.71 to 1.05 per 100,000). Median age at presentation was 1 year, with 82% in New York Heart Association class III to IV. Causes of heart failure included dilated cardiomyopathy (50 idiopathic, 8 familial), probable myocarditis (23), occult arrhythmia (7), anthracycline toxicity (5), metabolic disease (4), left ventricular noncompaction (3), and other (4). Overall 1-year survival was 82%, and event (death or transplantation)-free survival was 66%. Regression analysis showed older age and reduced systolic function on admission echocardiogram increased the event risk. Only 8% of event-free survivors (n=69) remained in New York Heart Association class III to IV, but 35 required readmission during the study period, and all but 8 remained on medication. CONCLUSIONS This first national prospective study of new-onset heart failure in children has shown an incidence of 0.87/100,000. Multivariable analysis of survival data indicates a better outcome for younger children and for those with better systolic function at presentation, but overall, one third of children die or require transplantation within 1 year of presentation.
Collapse
Affiliation(s)
- Rachel E Andrews
- Department of Congenital Heart Disease, Evelina Children's Hospital, Guys' and St Thomas' NHS Trust, London, United Kingdom
| | | | | | | | | |
Collapse
|
18
|
|
19
|
Alvarez JA, Wilkinson JD, Lipshultz SE. Outcome Predictors for Pediatric Dilated Cardiomyopathy: A Systematic Review. PROGRESS IN PEDIATRIC CARDIOLOGY 2007; 23:25-32. [PMID: 19701490 DOI: 10.1016/j.ppedcard.2007.05.009] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Dilated cardiomyopathy comprises the largest group of pediatric cardiomyopathy functional types and is the most common indication for heart transplant in children over 5 years old. Prognostic factors for this condition have long been sought by many researchers. In a systematic review of these factors, we found 32 relevant articles published since 1976. Four studies report finding no predictive factors. In the remaining 28 studies, several factors indicating better prognosis stand out across multiple articles: younger age at diagnosis, higher left-ventricular fractional shortening and ejection fraction, and the presence of myocarditis. Results for other factors conflict across studies: severe mitral regurgitation, arrhythmias, and a family history of cardiomyopathy. Elevated left-ventricular end diastolic pressure was statistically significant in two studies, but it may be of limited utility as a result of its invasiveness. Although most children have congestive heart failure at presentation, only two studies found it to be a significant predictor of mortality. The largest study of this factor qualified the increased risk to 1 year after presentation. Other significant predictors that have not been analyzed or reported by more than one study group, are right ventricular failure and impaired cardiac adrenergic innervation, as detected by radiolabeled meta-iodobenzylguanidine imaging. Although 1- and 5-year survival rates have steadily improved, as more children with DCM receive cardiac transplants, event-free survival rates (the absence of "heart death" resulting in death or transplant) are similar to those from decades ago. A unified risk algorithm may assist in clinical decision-making but requires more studies. Other studies are needed to assess the post-transplant survival experience.
Collapse
Affiliation(s)
- Jorge A Alvarez
- Department of Pediatrics, Leonard M. Miller School of Medicine, University of Miami, Miami, FL USA
| | | | | |
Collapse
|
20
|
Azevedo VMP, Santos MA, Albanesi Filho FM, Castier MB, Tura BR, Amino JGC. Outcome factors of idiopathic dilated cardiomyopathy in children - a long-term follow-up review. Cardiol Young 2007; 17:175-84. [PMID: 17244382 DOI: 10.1017/s1047951107000170] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/23/2006] [Indexed: 11/07/2022]
Abstract
BACKGROUND Idiopathic dilated cardiomyopathy in children has a high rate of mortality. Cardiac transplantation is the treatment of choice in those who fail to respond to therapeutics. Several studies have been carried out to determine unfavourable prognoses, and to provide an early indication for cardiac transplantation. Nevertheless, no consensus has been reached on the matter. OBJECTIVE To propose predictors of death in children with idiopathic dilated cardiomyopathy. METHODS We reviewed data extending over 22 years from 142 consecutive children with idiopathic dilated cardiomyopathy, of whom 36 died. The criteria for inclusion were the presence of congestive heart failure or cardiomegaly in a routine chest X-ray, confirmed by enlargement and hypo kinesis of the left ventricle in the echocardiogram. We included asymptomatic children in functional class I. Based on Cox's analysis of clinical and laboratory data, we sought any predictors of death. RESULTS In univariate analysis, the predictors were functional class IV at presentation (p equal to 0.0001), dyspnoea (p equal to 0.0096), and reduced pedal pulses (p equal to 0.0413). In chest X-ray, they were maximal cardiothoracic ratio (p equal to 0.0001) and pulmonary congestion (p equal to 0.0072). In the electrocardiogram, right atrium overload (p equal to 0.0118), ventricular arrhythmias (p equal to 0.0148) and heart rate (p equal to 0.027). In the echocardiogram, mitral regurgitation of grade 3 to 4 (p equal to 0.002), the left atrial to aortic ratio (p equal to 0.0001), and left ventricle ejection fraction (p equal to 0.0266). In multivariate analysis, the independent predictors were maximum cardiothoracic ratio (p equal to 0.0001), left ventricle ejection fraction (p equal to 0.0013), mitral regurgitation of grade 3 or 4 (p equal to 0.0017), functional class IV at presentation (p equal to 0.0028), and ventricular arrhythmias (p equal to 0.0253). CONCLUSION Children, who have these predictors of death should be considered for early heart transplantation when no improvement is observed in clinical treatment.
Collapse
Affiliation(s)
- Vitor Manuel P Azevedo
- Department of Research, National Institute of Cardiology Laranjeiras, Rio de Janeiro, Brazil.
| | | | | | | | | | | |
Collapse
|
21
|
Voss A, Schroeder R, Truebner S, Goernig M, Figulla HR, Schirdewan A. Comparison of nonlinear methods symbolic dynamics, detrended fluctuation, and Poincare plot analysis in risk stratification in patients with dilated cardiomyopathy. CHAOS (WOODBURY, N.Y.) 2007; 17:015120. [PMID: 17411277 DOI: 10.1063/1.2404633] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Dilated cardiomyopathy (DCM) has an incidence of about 20100 000 new cases per annum and accounts for nearly 10 000 deaths per year in the United States. Approximately 36% of patients with dilated cardiomyopathy (DCM) suffer from cardiac death within five years after diagnosis. Currently applied methods for an early risk prediction in DCM patients are rather insufficient. The objective of this study was to investigate the suitability of short-term nonlinear methods symbolic dynamics (STSD), detrended fluctuation (DFA), and Poincare plot analysis (PPA) for risk stratification in these patients. From 91 DCM patients and 30 healthy subjects (REF), heart rate and blood pressure variability (HRV, BPV), STSD, DFA, and PPA were analyzed. Measures from BPV analysis, DFA, and PPA revealed highly significant differences (p<0.0011) discriminating REF and DCM. For risk stratification in DCM patients, four parameters from BPV analysis, STSD, and PPA revealed significant differences between low and high risk (maximum sensitivity: 90%, specificity: 90%). These results suggest that STSD and PPA are useful nonlinear methods for enhanced risk stratification in DCM patients.
Collapse
Affiliation(s)
- Andreas Voss
- Department of Medical Engineering, University of Applied Sciences Jena, Carl-Zeiss-Promenade 2, D-07745 Jena, Germany.
| | | | | | | | | | | |
Collapse
|
22
|
Canter CE, Shaddy RE, Bernstein D, Hsu DT, Chrisant MRK, Kirklin JK, Kanter KR, Higgins RSD, Blume ED, Rosenthal DN, Boucek MM, Uzark KC, Friedman AH, Friedman AH, Young JK. Indications for Heart Transplantation in Pediatric Heart Disease. Circulation 2007; 115:658-76. [PMID: 17261651 DOI: 10.1161/circulationaha.106.180449] [Citation(s) in RCA: 175] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Since the initial utilization of heart transplantation as therapy for end-stage pediatric heart disease, improvements have occurred in outcomes with heart transplantation and surgical therapies for congenital heart disease along with the application of medical therapies to pediatric heart failure that have improved outcomes in adults. These events justify a reevaluation of the indications for heart transplantation in congenital heart disease and other causes of pediatric heart failure.
Methods and Results—
A working group was commissioned to review accumulated experience with pediatric heart transplantation and its use in patients with unrepaired and/or previously repaired or palliated congenital heart disease (children and adults), in patients with pediatric cardiomyopathies, and in pediatric patients with prior heart transplantation. Evidence-based guidelines for the indications for heart transplantation or retransplantation for these conditions were developed.
Conclusions—
This evaluation has led to the development and refinement of indications for heart transplantation for patients with congenital heart disease and pediatric cardiomyopathies in addition to indications for pediatric heart retransplantation.
Collapse
|
23
|
Daubeney PEF, Nugent AW, Chondros P, Carlin JB, Colan SD, Cheung M, Davis AM, Chow CW, Weintraub RG. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation 2006; 114:2671-8. [PMID: 17116768 DOI: 10.1161/circulationaha.106.635128] [Citation(s) in RCA: 164] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Despite considerable mortality, population-based prognostic factors for childhood dilated cardiomyopathy are lacking. METHODS AND RESULTS A population-based cohort study was undertaken of all children in Australia who presented with cardiomyopathy at age 0 to 10 years between January 1, 1987, and December 31, 1996. A single cardiologist analyzed all cardiac investigations, and a single pathologist analyzed histopathological material. There were 184 subjects with dilated cardiomyopathy. Positive viral identification or lymphocytic myocarditis was found in 30 (68.2%) of 44 cases with available early histology and 8 of 9 cases presenting with sudden death. Freedom from death or transplantation was 72% (95% CI, 65% to 78%) 1 year after presentation and 63% (95% CI, 55% to 70%) at 5 years. By proportional hazards regression analysis, risk factors for death or transplantation comprised age >5 years at presentation (hazard ratio 5.6, 95% CI, 2.6 to 12.0), familial dilated cardiomyopathy (hazard ratio, 2.9; 95% CI, 1.5 to 5.6), lower initial fractional shortening z score (hazard ratio per z-score unit, 0.75; 95% CI, 0.65 to 0.87), and failure to increase fractional shortening z score during follow-up (hazard ratio per unit increase, 0.68; 95% CI, 0.58 to 0.79). At follow-up, 78 (44.6%) of 175 cases diagnosed during life have no symptoms and are not taking any cardiac medication. CONCLUSIONS Early mortality is high in childhood dilated cardiomyopathy, but the clinical status of long-term survivors is good. This population-based study identifies children at risk of adverse events.
Collapse
Affiliation(s)
- Piers E F Daubeney
- Department of Cardiology, Royal Children's Hospital, Melbourne, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
McCrindle BW, Karamlou T, Wong H, Gangam N, Trivedi KR, Lee KJ, Benson LN. Presentation, management and outcomes of thrombosis for children with cardiomyopathy. Can J Cardiol 2006; 22:685-90. [PMID: 16801999 PMCID: PMC2560561 DOI: 10.1016/s0828-282x(06)70937-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Thrombosis in children with dilated and inflammatory cardiomyopathy is an unpredictable complication with potentially important morbidity. OBJECTIVE To determine the prevalence, associated factors, management and outcomes of thrombosis in this setting. METHODS Data were obtained from review of medical records. Factors associated with thrombosis and the impact on outcome were sought. RESULTS From 1990 to 1998, 66 patients that presented with dilated cardiomyopathy were followed for a median interval of 1.4 years (range 0 to 9.79 years) from first presentation. Thrombosis was diagnosed in four patients at presentation and in four patients during follow-up. Thrombosis was noted in one additional patient at examination after death. The overall nine-year period prevalence of thrombosis was 14%. Anticoagulation was started at presentation in 31% of patients. The mean left ventricular ejection fraction at presentation was significantly lower in those given anticoagulation (19+/-8%) versus those who were not (32+/-15%; P < 0.001). The mean ejection fraction at presentation was similar in those patients with (25+/-10%) versus those without thrombosis (28+/-15%; P = 0.44). During follow-up, 11 patients died and seven underwent cardiac transplantation. Kaplan-Meier estimates of freedom from death or transplantation were 88% at three months, 81% at one year and 70% at five years. Survival free of transplantation was not affected by thrombosis. CONCLUSIONS Thrombosis is common in children with cardiomyopathy, can occur at any time in the patients' clinical course and is not related to clinical features or survival free of transplantation. The relevance and prevention of thrombosis in this setting remains unclear.
Collapse
Affiliation(s)
- Brian W McCrindle
- Division of Cardiology, Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada.
| | | | | | | | | | | | | |
Collapse
|
25
|
Blume ED, Canter CE, Spicer R, Gauvreau K, Colan S, Jenkins KJ. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006; 27:336-42. [PMID: 16596434 DOI: 10.1007/s00246-005-1159-1] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The objective of this study was to evaluate the safety and efficacy of carvedilol in pediatric patients with stable moderate heart failure. We performed a single-arm prospective drug trial at three academic medical centers and the results were compared to historical controls. Patients were 3 months to 17 years old with an ejection fraction <40% in the systemic ventricle for at least 3 months on maximal medical therapy including ACE inhibitors. Treated patients were started on 0.1 mg/kg/day and uptitrated to 0.8 mg/kg/day or the maximal tolerated dose. Echocardiographic parameters of function were prospectively measured at entry and at 6 months. Two composite endpoints were recorded: severe decline in status and significant clinical change. Adverse events were reviewed by a safety committee. Data were also collected from untreated controls with dilated cardiomyopathy meeting entry criteria, assessed over a similar time frame. Twenty patients [12 dilated cardiomyopathy (DCM) and 8 congenital] with a median age of 8.4 years (range, 8 months to 17.8 years) were treated with carvedilol. Three patients discontinued the drug during the study. At entry, there was no statistical difference in age, weight, or ejection fraction between the treated group and controls. The ejection fraction of the treated DCM group improved significantly from entry to 6 months (median, 31 to 40%, p = 0.04), with no significant change in ejection fraction in the control group [median, 29 to 27%, p = not significant (NS)]. The median increase in ejection fraction was larger for the treated DCM group than for the untreated DCM controls (7 vs 0%, p = 0.05). By Kaplan-Meier analysis, time to death or transplant tended to be longer in treated patients (p = 0.07). The difference in the proportion of patients with severe decline in status or significant clinical change in the treated group was not significant compared to the controls (5 vs 12%, p = NS). We conclude that in this prospective protocol of pediatric patients, the use of adjunct carvedilol in the DCM group improved ejection fraction compared to untreated controls and trended toward delaying time to transplant or death.
Collapse
Affiliation(s)
- E D Blume
- Department of Cardiology, Children's Hospital, Boston, 300 Longwood Avenue, Boston, MA 02115, USA.
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
OBJECTIVES The present study determined the prevalence of dilated cardiomyopathy together with prolonged corrected QT (QTc) intervals in children. The study also examined whether an association exists between prolonged QTc intervals and ventricular dysrhythmia in a patient cohort with dilated cardiomyopathy. BACKGROUND The morbidity and mortality for pediatric patients with dilated cardiomyopathy remains high and is a clinical challenge. The patient population includes a significant number of Hutterite patients with metabolic disease associated with dilated cardiomyopathy. METHODS Thirty-eight pediatric patients with dilated cardiomyopathy were reviewed for the presence of prolonged QTc and dysrhythmias. Eleven patients had a metabolic etiology for their dilated cardiomyopathy. RESULTS Thirty-six per cent of the patient cohort had a long QTc interval. After 50 months of follow-up, the probability of survival for a child with a long QTc interval was approximately 50%. The probability of survival for a child with a normal QTc interval was 72%. Seventy per cent of the patients who died had a metabolic etiology for their dilated cardiomyopathy and a long QTc. CONCLUSIONS Dilated cardiomyopathy may be associated with a prolonged QTc and may increase the patient's risk for sudden death. The presence of a metabolic etiology for dilated cardiomyopathy increases the risk of death.
Collapse
MESH Headings
- Adolescent
- Alberta/epidemiology
- Arrhythmias, Cardiac/complications
- Arrhythmias, Cardiac/epidemiology
- Arrhythmias, Cardiac/mortality
- Cardiomyopathy, Dilated/complications
- Cardiomyopathy, Dilated/epidemiology
- Cardiomyopathy, Dilated/metabolism
- Cardiomyopathy, Dilated/mortality
- Cardiomyopathy, Dilated/physiopathology
- Child
- Child, Preschool
- Cohort Studies
- Electrocardiography
- Female
- Humans
- Infant
- Infant, Newborn
- Long QT Syndrome/epidemiology
- Long QT Syndrome/etiology
- Long QT Syndrome/mortality
- Long QT Syndrome/physiopathology
- Male
- Medical Records
- Myocardium/metabolism
- Prevalence
- Retrospective Studies
- Survival Rate
Collapse
Affiliation(s)
| | - R Michael Giuffre
- Department of Pediatrics
- Department of Cardiology, Faculty of Medicine, University of Calgary, Alberta
- Correspondence: Dr Michael Giuffre, Alberta Children’s Hospital, 1820 Richmond Road South West, Calgary, Alberta T2T 5C7. Telephone 403-943-7858, fax 403-943-7621, e-mail
| |
Collapse
|
27
|
Abstract
Pediatric patients with dilated cardiomyopathy can initially be present for medical attention with non-specific and misleading signs and symptoms. We present the case of a 7-year-old girl with vague complaints of fever, vomiting, and abdominal pain and cardiac murmur on physical exam who progressed to congestive heart failure before her dilated cardiomyopathy was diagnosed. Clinicians should maintain a high index of suspicion for dilated cardiomyopathy in any patient with cardiac murmur and systematic symptoms.
Collapse
Affiliation(s)
- Eric C Hoppa
- Department of Pediatrics, University of Connecticut School of Medicine, Connecticut Children's Medical Center, Hartford, CT, USA.
| | | |
Collapse
|
28
|
Weng KP, Lin CC, Huang SH, Hsieh KS. Idiopathic dilated cardiomyopathy in children: a single medical center's experience. J Chin Med Assoc 2005; 68:368-72. [PMID: 16138715 DOI: 10.1016/s1726-4901(09)70177-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND The prognosis of patients with idiopathic dilated cardiomyopathy (DCM) is poor. Most patients die while waiting for cardiac transplantation because of the small number of donors in Taiwan. The purpose of this study was to review our experience with pediatric patients diagnosed with idiopathic DCM and attempt to discover prognostic factors. METHODS Eighteen patients with idiopathic DCM presenting between 1990 and 2004 were identified. They were classified into 2 groups according to outcome: group 1 comprised 13 patients who died; group 2 comprised 5 who survived. Clinical findings and laboratory investigations were compared between the 2 groups. RESULTS The age at initial diagnosis for the 18 patients (11 males, 7 females) ranged from fetus to 13 years (median, 3 months). The follow-up period ranged from 12 days to 44 months (median, 7 months) in group 1, and from 1 to 48 months (median, 39 months) in group 2. Of the 18 patients, 13 (72%) died: 11 died from severe heart failure while waiting for cardiac transplantation. The cumulative survival rate was 50% at 1 year and 28% at 4 years. The presence of arrhythmia and low left ventricular ejection fraction were predictive of a poor outcome. CONCLUSION The diagnosis of idiopathic DCM in children is associated with a generally poor prognosis. The lack of available donors results in significant mortality for pediatric patients awaiting transplantation. Advocating organ donation to increase the size of the organ donor pool is needed to significantly reduce the mortality rate in such patients.
Collapse
Affiliation(s)
- Ken-Pen Weng
- Department of Pediatrics, Kaohsiung Veterans General Hospital, Taiwan
| | | | | | | |
Collapse
|
29
|
Soongswang J, Sangtawesin C, Durongpisitkul K, Laohaprasitiporn D, Nana A, Punlee K, Kangkagate C. The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. Pediatr Cardiol 2005; 26:361-6. [PMID: 16374685 DOI: 10.1007/s00246-004-0742-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The objective of this study was to assess the effect of coenzyme Q10 (CoQ10) as supplementation to conventional antifailure drugs on quality of life and cardiac function in children with chronic heart failure due to dilated cardiomyopathy (DCM). The study was an open-label prospective study performed in two of the largest pediatric centers in Thailand from August 2000 to June 2003. A total of 15 patients with idiopathic chronic DCM were included, with the median age of 4.4 years (range, 0.6-16.3). Presenting symptoms were congestive heart failure in 12 cases (80%), cardiogenic shock in 2 cases (13.3%), and cardiac arrhythmia in 1 case (6.7%). Sixty-one percent of patients were in the New York Heart Association functional class 2 (NYHA 2), 31% in NYHA 3, and 8% in NYHA 4. Cardiothoracic ratio from chest x-ray, left ventricular ejection fraction, and left ventricular end diastolic dimension in echocardiogram were 0.62 (range, 0.55-0.78), 30% (range, 20-40), and 5.2 cm (range, 3.8-6.5), respectively. CoQ10 was given at a dosage of 3.1 ? 0.6 mg/kg/day for 9 months as a supplementation to a fixed amount of conventional antifailure drugs throughout the study. At follow-up periods of 1, 3, 6, and 9 months, NYHA functional class was significantly improved, as was CT ratio and QRS duration at 3 and 9 months follow-up with CoQ10 when compared to the baseline and post-discontinuation of CoQ10 at 9 months (range, 4.8-10.8). However, when multiple comparisons were taken into consideration, there was no statistical significant improvement. In addition to the conventional antifailure drugs, CoQ10 may improve NYHA class and CT ratio and shorten ventricular depolarization in children with chronic idiopathic DCM.
Collapse
Affiliation(s)
- J Soongswang
- Division of Cardiology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, 10700 Bangkok, Thailand.
| | | | | | | | | | | | | |
Collapse
|
30
|
Rosenthal D, Chrisant MRK, Edens E, Mahony L, Canter C, Colan S, Dubin A, Lamour J, Ross R, Shaddy R, Addonizio L, Beerman L, Berger S, Bernstein D, Blume E, Boucek M, Checchia P, Dipchand A, Drummond-Webb J, Fricker J, Friedman R, Hallowell S, Jaquiss R, Mital S, Pahl E, Pearce FB, Pearce B, Rhodes L, Rotondo K, Rusconi P, Scheel J, Pal Singh T, Towbin J. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transplant 2005; 23:1313-33. [PMID: 15607659 DOI: 10.1016/j.healun.2004.03.018] [Citation(s) in RCA: 178] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- David Rosenthal
- International Society for Heart and Lung Transplantation, Addison, Texas.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Tsirka AE, Trinkaus K, Chen SC, Lipshultz SE, Towbin JA, Colan SD, Exil V, Strauss AW, Canter CE. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol 2004; 44:391-7. [PMID: 15261937 DOI: 10.1016/j.jacc.2004.04.035] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2003] [Revised: 02/25/2004] [Accepted: 04/06/2004] [Indexed: 11/25/2022]
Abstract
OBJECTIVES We studied the outcomes of pediatric patients diagnosed with dilated cardiomyopathy (DCM) and their relation to epidemiologic and echocardiographic variables at the time of presentation. BACKGROUND The outcome of pediatric DCM patients ranges from recovery to a 50% to 60% chance of death within five years of diagnosis. The impact of heart transplantation and other emerging therapies on the outcomes of pediatric DCM patients is uncertain. METHODS We performed a retrospective study of the outcomes in 91 pediatric patients diagnosed with DCM from 1990 to 1999. Routine therapy included use of digoxin, diuretics, angiotensin-converting enzyme inhibitors, and heart transplantation. RESULTS At the time of last follow-up, 11 patients (12%) had died without transplantation; 20 (22%) underwent transplantation; 27 (30%) had persistent cardiomyopathy; and 33 (36%) had recovery of left ventricular systolic function. Overall actuarial one-year survival was 90%, and five-year survival was 83%. However, actuarial freedom from "heart death" (death or transplantation) was only 70% at one year and 58% at five years. Multivariate analysis found age <1 year (hazard ratio 7.1), age >12 years (hazard ratio 4.5), and female gender (hazard ratio 3.0) to be significantly associated with a greater risk of death or transplantation and a higher left ventricular shortening fraction at presentation (hazard ratio 0.92), with a slightly decreased risk of death or transplantation. CONCLUSIONS Pediatric DCM patients continue to have multiple outcomes, with recovery of left ventricular systolic function occurring most frequently. Utilization of heart transplantation has led to improved survival after the diagnosis of pediatric DCM.
Collapse
Affiliation(s)
- Anna E Tsirka
- Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Rusconi P, Gómez-Marín O, Rossique-González M, Redha E, Marín JR, Lon-Young M, Wolff GS. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 2004; 23:832-8. [PMID: 15261177 DOI: 10.1016/j.healun.2003.07.025] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2003] [Accepted: 07/14/2003] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND Carvedilol reduces mortality and hospitalization in adults with congestive heart failure. Limited information is available about its use in children. METHODS We reviewed the medical records of 24 children with dilated cardiomyopathy and left ventricular ejection fraction of <or=40%, who were treated with carvedilol as adjunct therapy to angiotensin-converting enzyme inhibitors, digoxin and diuretics. RESULTS Carvedilol was initiated 14.3 +/- 23.3 (mean +/- SD) months after the diagnosis of cardiomyopathy. Mean age at initiation of therapy was 7.2 +/- 6.4 years. The mean initial and maximum doses were 0.15 +/- 0.09 and 0.98 +/- 0.26 mg/kg/day. Adverse effects occurred in 5 patients (21%). Two patients (8%) required discontinuation of the drug within 5 weeks of the initial dose. The remaining 22 patients tolerated carvedilol for a mean follow-up period of 26.6 +/- 14.7 months. Among these 22 patients, mean left ventricular ejection fraction improved from 24.6 +/- 7.6% to 42.2 +/- 14.2% (p < 0.001), and mean sphericity index from 0.86 +/- 0.11 to 0.74 +/- 0.10 (p < 0.001). New York Heart Association functional class improved in 15 patients (68%). One patient (4%) died and 3 (14%) were transplanted. CONCLUSIONS Carvedilol, in addition to standard therapy for dilated cardiomyopathy in children improves cardiac function and symptoms; it is well tolerated, with minimal adverse effects, but close monitoring is necessary as it might worsen congestive heart failure and precipitate asthma. Control studies are necessary to assess the effect of carvedilol on mortality and hospitalization rates.
Collapse
Affiliation(s)
- Paolo Rusconi
- Department of Pediatrics, University of Miami School of Medicine, Miami, Florida 33101, USA.
| | | | | | | | | | | | | |
Collapse
|
33
|
Affiliation(s)
- Mark Boucek
- Section of Cardiology, Children's Hospital, Denver, CO 80218, USA.
| |
Collapse
|
34
|
Abstract
Dilated cardiomyopathy (DCM) refers to a group of conditions of diverse etiology in which both ventricles are enlarged with reduced contractility. Certain correctable conditions associated with ventricular dysfunction can masquerade as DCM. Most of them can be identified with relatively inexpensive and readily available tests. A typical diagnostic work-up for a child with DCM also includes a number of investigations to identify the underlying cause, some of which are expensive and sophisticated. The average center in the developing world often does not have the facilities to carry out these investigations. The results of many of these investigations typically do not translate into a specific management strategy that makes a difference to prognosis. A significant number of children with DCM will eventually develop end-stage heart failure that requires cardiac transplantation with or without bridging procedures. This is an unrealistic option for the developing world. The management strategy of childhood DCM in the developing world needs to be tailored to the resources available with in a manner such that the overall prognosis is not substantially affected.
Collapse
Affiliation(s)
- R Krishna Kumar
- Amrita Institute of Medical Sciences and Research Center, Kochi, Kerala, India.
| |
Collapse
|
35
|
Nugent AW, Davis AM, Kleinert S, Wilkinson JL, Weintraub RG. Clinical, electrocardiographic, and histologic correlations in children with dilated cardiomyopathy. J Heart Lung Transplant 2001; 20:1152-7. [PMID: 11704474 DOI: 10.1016/s1053-2498(01)00334-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
OBJECTIVE To determine whether presenting electrocardiography is related to histologic findings and clinical outcomes in children with dilated cardiomyopathy. BACKGROUND Lymphocytic myocarditis is an important cause of childhood dilated cardiomyopathy, the outcome of which is unclear. The results of non-invasive investigations are often used to infer the presence or absence of lymphocytic myocarditis. METHODS Thirty-four children, presenting acutely with dilated cardiomyopathy, underwent both early electrocardiography and endomyocardial biopsy. The parameters examined included heart rate, PR, QRS, and corrected QT intervals, R-wave voltages in Leads V(1) and V(6), S-wave voltages in Leads V(1) and V(6), and sum of SV(1) and RV(6). We expressed measurements as Z scores, based on published normal values for age and gender. RESULTS A total of 15 patients had lymphocytic myocarditis on endomyocardial biopsy (Group I), and 19 had non-specific histologic findings (Group II). We did not distinguish the 2 groups by age, time to endomyocardial biopsy, or duration of follow-up. Group I patients had significantly smaller R-wave Z scores in Leads V(1) and V(6), and combined S in V(1) and R in V(6) Z scores (p < 0.02 for each). The positive and negative predictive values of an R-wave amplitude in V(6) < 5th percentile were 75% and 65%, respectively, for the diagnosis of lymphocytic myocarditis. An R-wave amplitude in V(6) > 95th percentile had a positive and negative predictive value of 80% and 63%, respectively, for the diagnosis of idiopathic dilated cardiomyopathy. Survival and freedom from late cardiac dysfunction were more common among Group I patients compared with Group II (p <or= 0.02 for both). CONCLUSION Myocardial histology cannot reliably be inferred from the presenting electrocardiogram. Survival and outcome for children with lymphocytic myocarditis is better than for those with non-specific histology.
Collapse
Affiliation(s)
- A W Nugent
- Department of Cardiology, Royal Children's Hospital, Parkville, Melbourne, Australia
| | | | | | | | | |
Collapse
|
36
|
Dubin AM, Van Hare GF, Collins KK, Bernstein D, Rosenthal DN. Survey of current practices in use of amiodarone and implantable cardioverter defibrillators in pediatric patients with end-stage heart failure. Am J Cardiol 2001; 88:809-10. [PMID: 11589857 DOI: 10.1016/s0002-9149(01)01860-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- A M Dubin
- Stanford University, Stanford, California, USA.
| | | | | | | | | |
Collapse
|
37
|
Venugopalan P, Houston AB, Agarwal AK. The outcome of idiopathic dilated cardiomyopathy and myocarditis in children from the west of Scotland. Int J Cardiol 2001; 78:135-41. [PMID: 11334657 DOI: 10.1016/s0167-5273(00)00480-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We analysed retrospectively all infants and children with idiopathic dilated cardiomyopathy (IDC) and myocarditis at the Regional Cardiac Centre of the Royal Hospital for Sick Children, Glasgow, during 1980-1997. Among the 39 patients with IDC, 25 (64%) were infants aged < 1 year, eight (20.5%) had wheezing as the presenting symptom, and only six (15%) had a significant cardiac murmur. Thirty-eight of thirty-nine patients diagnosed in life were followed-up for 1 day to 15 years (median 3 years). Twelve of the thirty-nine (31%) died, six deaths were within a week of presentation and the rest within a year. The survival at 1 year and at 12 years was 0.69 (95% CI 0.54 to 0.84). Fourteen patients had histologically proven myocarditis, and all 9/14 (64%) detected at post-mortem and one of the five diagnosed in life died. Patients with myocarditis exhibited an actuarial survival of 0.29 (95% CI 0.04 to 0.53) at 1 year and at 9 years, significantly lower than IDC patients (log rank 9.8, P < 0.01). There was no difference in the outcome for patients with positive or negative Coxsackie titres or who presented in the 1980s and in the 1990s. No risk factor that independently influenced the outcome or survival could be identified in either group. Thus our study from a relatively well-defined population of the west of Scotland showed that a significant proportion of children with IDC and myocarditis died in the first week of illness and that patients with myocarditis had shorter survival.
Collapse
Affiliation(s)
- P Venugopalan
- Department of Paediatric Cardiology, Royal Hospital for Sick Children, Scotland, Glasgow, UK.
| | | | | |
Collapse
|
38
|
Bruns LA, Chrisant MK, Lamour JM, Shaddy RE, Pahl E, Blume ED, Hallowell S, Addonizio LJ, Canter CE. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001; 138:505-11. [PMID: 11295713 DOI: 10.1067/mpd.2001.113045] [Citation(s) in RCA: 149] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE The objective was to determine the dosing, efficacy, and side effects of the nonselective beta-blocker carvedilol for the management of heart failure in children. STUDY DESIGN Carvedilol use in addition to standard medical therapy for pediatric heart failure was reviewed at 6 centers. RESULTS Children with dilated cardiomyopathy (80%) and congenital heart disease (20%), age 3 months to 19 years (n = 46), were treated with carvedilol. The average initial dose was 0.08 mg/kg, uptitrated over a mean of 11.3 weeks to an average maintenance dose of 0.46 mg/kg. After 3 months on carvedilol, there were improvements in modified New York Heart Association class in 67% of patients (P =.0005, chi2 analysis) and improvement in mean shortening fraction from 16.2% to 19.0% (P =.005, paired t test). Side effects, mainly dizziness, hypotension, and headache, occurred in 54% of patients but were well tolerated. Adverse outcomes (death, cardiac transplantation, and ventricular-assist device placement) occurred in 30% of patients. CONCLUSIONS Carvedilol as an adjunct to standard therapy for pediatric heart failure improves symptoms and left ventricular function. Side effects are common but well tolerated. Further prospective study is required to determine the effect of carvedilol on survival and to clearly define its role in pediatric heart failure therapy.
Collapse
Affiliation(s)
- L A Bruns
- Division of Cardiology, St Louis Children's Hospital, Washington University, St Louis, Missouri 63110, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Seliem MA, Mansara KB, Palileo M, Ye X, Zhang Z, Benson DW. Evidence for autosomal recessive inheritance of infantile dilated cardiomyopathy: studies from the Eastern Province of Saudi Arabia. Pediatr Res 2000; 48:770-5. [PMID: 11102545 DOI: 10.1203/00006450-200012000-00012] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Familial dilated cardiomyopathy is being increasingly recognized, but affected individuals <10 y are rarely identified. We describe the natural history of dilated cardiomyopathy and evaluate the mode of inheritance among infants of Arab descent from the Eastern Province of Saudi Arabia. We evaluated 55 consecutive cases of dilated cardiomyopathy in patients <10 y of age seen during a 5-y interval. Echocardiography was the primary diagnostic modality. The 55 cases represented 20% of the offspring of 41 families of Arab descent. In 19 families (46%), parents were first cousins; there was no obvious consanguinity in 22 families (54%). Age at presentation was <30 mo (95%) (range, 1 to 100 mo); males (38%) and females (62%) were affected. Patients died (25 patients, 46%), improved (15 patients, 27%), or recovered (15 patients, 27%). The left ventricular shortening fraction at diagnosis ranged from 5 to 28% and did not differ in those who died, improved, or recovered. Complex segregation analysis of the family data using the mixed model of inheritance showed that a model of recessive inheritance best fits the data. Recessively inherited dilated cardiomyopathy has been infrequently reported, perhaps because it may be difficult to recognize in other patient groups in which consanguineous marriage is uncommon and the number of children per family is small. In the setting of consanguineous marriage, homozygosity mapping should lead to identification of the gene(s) causing dilated cardiomyopathy in the families we studied.
Collapse
Affiliation(s)
- M A Seliem
- Specialty Pediatrics Division, Saudi Aramco-Dhahran Health Center, Dhahran 31311, Saudi Arabia
| | | | | | | | | | | |
Collapse
|
40
|
Abstract
Left ventricular reduction has shown promise as a treatment for end-stage dilated cardiomyopathy, with restoration of the physiologic ratio between myocardial mass and left ventricular diameter. We present a case of successful partial left ventriculectomy utilizing both lateral and septal wall excision as treatment of dilated cardiomyopathy in a 9-month-old patient.
Collapse
Affiliation(s)
- L A Vricella
- Division of Cardiothoracic Surgery, Loma Linda University Medical Center and Children's Hospital, California 92354, USA
| | | | | | | |
Collapse
|
41
|
Abstract
Cardiomyopathy is defined as primary myocardial dysfunction which is not due to hypertensive, valvular, congenital, coronary or pulmonary vascular disease. This term usually denotes a dismal prognosis short of cardiac transplantation. However, several organic diseases of the heart can result in right or left ventricular dysfunction resulting in congestive heart failure and prompting the physician to label them as cardiomyopathy; the etiological factor is overlooked as it produces very subtle features. Therefore, before labelling any child as cardiomyopathic, all possible causes of ventricular dysfunction must be excluded by clinical and investigative means. The causes of "treatable cardiomyopathy" include mechanical factors as critical aortic stenosis and pulmonic stenosis, severe coarctation of aorta in an infant and aortaarteritis is an older child. Some of the persistent arrhythmias like atrial tachycardia, fibrillation, paroxysmal junctional re-entrant tachycardia are also known for causing ventricular dysfunction producing tachycardiomyopathy. Treatment of arrhythmia improves the ventricular function. Myocardial ischemia as a result of congenital coronary anomaly (commonest being anomalous origin of left coronary artery from pulmonary artery) can also present with a cardiomyopathy like picture. Early surgical correction is very rewarding. Finally, some of the metabolic conditions like creatinine and thiamine deficiency can also produce ventricular dilatation and dysfunction. In conclusion, the so called cardiomyopathy like picture can be produced because of several reasons and an attempt must be made to identify them.
Collapse
Affiliation(s)
- S S Prabhu
- Department of Pediatrics, B.J. Wadia Hospital for Children, Parel, Mumbai
| | | |
Collapse
|
42
|
Grenier MA, Osganian SK, Cox GF, Towbin JA, Colan SD, Lurie PR, Sleeper LA, Orav EJ, Lipshultz SE. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J 2000; 139:S86-95. [PMID: 10650321 DOI: 10.1067/mhj.2000.103933] [Citation(s) in RCA: 94] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The Pediatric Cardiomyopathy Registry (PCMR) was established to describe the epidemiologic features and clinical course of selected cardiomyopathies in patients aged 18 years or younger and to promote the development of etiology-specific treatments. Sixty-one private and institutional pediatric cardiomyopathy practices in the United States and Canada were recruited to participate in the PCMR. The registry consists of a prospective, population-based cohort of patients in 2 regions (New England and the Central Southwestern United States) and a retrospective cohort of patients diagnosed between 1991 and 1996. Annual follow-up data are collected on all patients. As of June 1999, the PCMR consisted of 337 prospectively identified and 990 retrospectively identified patients. The PCMR has demonstrated the feasibility of establishing a large database of sociodemographic and clinical information on children with pediatric cardiomyopathy. Through this cooperative effort, the PCMR will obtain precise estimates of the incidence of pediatric cardiomyopathy and a better understanding of the natural history of this disease.
Collapse
Affiliation(s)
- M A Grenier
- Children's Hospital at Strong, University of Rochester, NY, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Pierpont ME, Breningstall GN, Stanley CA, Singh A. Familial carnitine transporter defect: A treatable cause of cardiomyopathy in children. Am Heart J 2000; 139:S96-S106. [PMID: 10650322 DOI: 10.1067/mhj.2000.103921] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Carnitine transporter defect is characterized by severely reduced transport of carnitine into skeletal muscle, fibroblasts, and renal tubules. All children with dilated cardiomyopathy or hypoglycemia and coma should be evaluated for this transporter defect because it is readily amenable to therapy that results in prolonged prevention of cardiac failure. This article details the cases of 3 children who have carnitine transporter defect, 2 of whom had severe dilated cardiomyopathy. Plasma and skeletal muscle carnitine levels were extremely low and both children were treated with oral L-carnitine, resulting in resolution of severe cardiomyopathy and prevention of recurrence or cardiac enlargement for more than 5 years. The third child had hypoglycemia and coma as presenting findings of the transporter defect and had mild left ventricular hypertrophy but no cardiac failure. The prognosis for long-term survival in pediatric dilated cardiomyopathy is poor. Children with carnitine transporter defect can have a different outcome if their underlying condition is detected early and treated medically.
Collapse
Affiliation(s)
- M E Pierpont
- Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA.
| | | | | | | |
Collapse
|
44
|
Fricker FJ, Addonizio L, Bernstein D, Boucek M, Boucek R, Canter C, Chinnock R, Chin C, Kichuk M, Lamour J, Pietra B, Morrow R, Rotundo K, Shaddy R, Schuette EP, Schowengerdt KO, Sondheimer H, Webber S. Heart transplantation in children: indications. Report of the Ad Hoc Subcommittee of the Pediatric Committee of the American Society of Transplantation (AST). Pediatr Transplant 1999; 3:333-42. [PMID: 10562980 DOI: 10.1034/j.1399-3046.1999.00045.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
This review details the indications for heart transplantation in children. Contraindications have evolved from absolute to relative. Controversial issues remain and this paper represents a consensus of more than a dozen centers that have programs that remain active performing pediatric heart transplants.
Collapse
|
45
|
Abstract
BACKGROUND The prognosis for children with idiopathic dilated cardiomyopathy (IDC) is variable. Patients who fail to exhibit improvement in left ventricular (LV) function have a high 1-year mortality rate, whereas improvement in LV fractional shortening (LVFS) to >15% is associated with better survival. However, complete recovery of LV performance to normal has not been examined. METHODS AND RESULTS The clinical features and echocardiograms of 63 children with IDC were reviewed. Sixteen patients (group 1) were identified who demonstrated progressive improvement in LVFS, ultimately recovering to within the normal range. They were compared with 47 patients (group 2) in whom LVFS remained depressed. Group 1 LVFS at first examination was 13.6% +/- 5.1%, z = -10.8 +/- 4.0, and improved to within the normal range (33.7% +/- 3.4%, z = -0.9 +/- 1. 4, P <.001). Group 2 initial LVFS was 13.6 +/- 2.3, z = -8.9 +/- 3.2 and did not change significantly (15.7% +/- 7.3%, z = -7.3 +/- 1.6). The LV was dilated at initial examination in all patients (z = 6.9 +/- 3.0). Recovery in group 1 was associated with a decrease in LV dimension to within the normal range (z = 1.3 +/- 1.6, P <.001), whereas the LV dimension in group 2 patients remained increased (z = 6.2 +/- 3.4). The mean follow-up time at which LV function was noted to be normal was 4.5 +/- 3.6 years (range 0.3 to 14 years). The total duration of follow-up was 6.5 +/- 5.2 years (range 1 to 16 years). CONCLUSIONS Complete recovery of LV function is possible in children with IDC. Recovery may occur within the first year after initial examination in some patients, but longer periods are needed in the majority of patients in whom LV function ultimately returned to normal.
Collapse
Affiliation(s)
- A B Lewis
- Division of Cardiology, Childrens Hospital Los Angeles, Department of Pediatrics, CA 90054-0070, USA
| |
Collapse
|
46
|
Dubin AM, Rosenthal DN, Chin C, Bernstein D. QT dispersion predicts ventricular arrhythmia in pediatric cardiomyopathy patients referred for heart transplantation. J Heart Lung Transplant 1999; 18:781-5. [PMID: 10512525 DOI: 10.1016/s1053-2498(99)00010-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND QT dispersion has been used in stratifying risk for sudden death in adults with dilated cardiomyopathy, but its role in the pediatric population has not been delineated. METHODS We reviewed electrocardiograms in pediatric patients with dilated cardiomyopathy referred for heart transplantation, to evaluate the role of QT dispersion in predicting malignant arrhythmias in these patients. Three groups were defined: Group I (n = 13) had dilated cardiomyopathy and malignant ventricular arrhythmias, Group II (n = 13) had dilated cardiomyopathy with no ventricular arrhythmias and Group III (n = 30) consisted of normals. QT dispersion was defined as the duration of the shortest QT subtracted from that of the longest. In addition, the standard deviation of the QT intervals was calculated for each ECG, using 12 leads. RESULTS QT dispersion was significantly prolonged in Group I (97 +/- 33 msec) compared to Group II (74 +/- 19 msec) and Group III (42 +/- 17 msec). QT standard deviation was also prolonged in Group I (30 +/- 11 msec) vs Group II (22 +/- 5 msec) and Group III (13 +/- 4 msec). Using a threshold value of 90 msec for QT dispersion or 25 msec for QT standard deviation, a sensitivity of 78% and a specificity of 70% was obtained for identifying patients who would subsequently develop ventricular arrhythmias. CONCLUSIONS In pediatric heart transplant candidates with dilated cardiomyopathy, QT dispersion and QT standard deviation identify patients at higher risk for the development of malignant ventricular arrhythmia. This simple test can be helpful in the evaluation and management of these patients awaiting transplantation.
Collapse
Affiliation(s)
- A M Dubin
- Stanford University, California, USA
| | | | | | | |
Collapse
|
47
|
Kitzmüller E, Gruber A, Marx M, Schlemmer M, Wimmer M, Richling B. Superselective Intra-Arterial Thrombolysis for Acute Cardioembolic Stroke in a Child with Idiopathic Dilated Cardiomyopathy. Interv Neuroradiol 1999; 5:187-94. [DOI: 10.1177/159101999900500213] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/1999] [Accepted: 04/03/1999] [Indexed: 11/17/2022] Open
Abstract
We describe a case of cardioembolic dominant hemisphere internal carotid artery occlusion in a child with idiopathic dilated cardiomyopathy. The patient was subjected to superselective local intra-arterial thrombolysis using recombinant tissue plasminogen activator (Alteplase; Actilyse®). In presence of good collateral flow local intra-arterial thrombolysis prevented a major dominant hemisphere ischaemic stroke, although post-interventional computed tomographic scans disclosed haemorrhagic conversion in the left corpus striatum. Forty eight months after ischaemic stroke and thrombolysis the patient is ambulatory with a moderate neurologic deficit.
Collapse
Affiliation(s)
| | - A. Gruber
- Departments of Neurosurgery; University of Vienna Medical School
| | | | | | | | - B. Richling
- Departments of Neurosurgery; University of Vienna Medical School
| |
Collapse
|
48
|
Abstract
Cardiomyopathies are diseases of the heart muscles. This article reviews the causes, clinical presentation, diagnosis, management, and long-term outcomes of dilated and hypertrophic cardiomyopathy.
Collapse
Affiliation(s)
- J A Towbin
- Department of Pediatrics (Cardiology), Molecular and Human Genetics, Texas Children's Hospital, Baylor College of Medicine, Houston, USA
| |
Collapse
|
49
|
Mathur A, Sims HF, Gopalakrishnan D, Gibson B, Rinaldo P, Vockley J, Hug G, Strauss AW. Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation 1999; 99:1337-43. [PMID: 10077518 DOI: 10.1161/01.cir.99.10.1337] [Citation(s) in RCA: 103] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Genetic defects are being increasingly recognized in the etiology of primary cardiomyopathy (CM). Very-long-chain acyl-CoA dehydrogenase (VLCAD) catalyzes the first step in the beta-oxidation spiral of fatty acid metabolism, the crucial pathway for cardiac energy production. METHODS AND RESULTS We studied 37 patients with CM, nonketotic hypoglycemia and hepatic dysfunction, skeletal myopathy, or sudden death in infancy with hepatic steatosis, features suggestive of fatty acid oxidation disorders. Single-stranded conformational variance was used to screen genomic DNA. DNA sequencing and mutational analysis revealed 21 different mutations on the VLCAD gene in 18 patients. Of the mutations, 80% were associated with CM. Severe CM in infancy was recognized in most patients (67%) at presentation. Hepatic dysfunction was common (33%). RNA blot analysis and VLCAD enzyme assays showed a severe reduction in VLCAD mRNA in patients with frame-shift or splice-site mutations and absent or severe reduction in enzyme activity in all. CONCLUSIONS Infantile CM is the most common clinical phenotype of VLCAD deficiency. Mutations in the human VLCAD gene are heterogeneous. Although mortality at presentation is high, both the metabolic disorder and cardiomyopathy are reversible.
Collapse
Affiliation(s)
- A Mathur
- Departments of Pediatrics, Medicine and Molecular Biology and Pharmacology, Washington University School of Medicine, St Louis Children's Hospital, St Louis, MO, USA
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
We describe three infants <3 months of age seen consecutively with dilated cardiomyopathy who presented initially with left bundle branch block on the surface 12-lead electrocardiogram. Each infant subsequently had a poor outcome: two died and one required heart transplantation. These results suggest that the presence of left bundle branch block on the 12-lead electrocardiogram conveys a poor prognosis in infants with dilated cardiomyopathy.
Collapse
Affiliation(s)
- J F Cnota
- Department of Pediatrics, Steele Memorial Children's Research Center, College of Medicine, University of Arizona, Tucson, USA
| | | |
Collapse
|